Paraneoplastic polyneuropathy

Summary

Paraneoplastic polyneuropathy (MONDO:0006888) is a disease. A subtype of polyneuropathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	paraneoplastic polyneuropathy
Mondo ID	MONDO:0006888
MeSH	D020364
DOID	DOID:8681
NCIT	C3981
SNOMED CT	77659000
UMLS	C0270932
MedGen	124380
GARD	0024499
MedDRA	10062289
Is cancer (heuristic)	no

Also known as: paraneoplastic polyneuropathy

Disease family

This is a subtype of polyneuropathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › peripheral neuropathy › polyneuropathy › paraneoplastic polyneuropathy

Related subtypes (9): idiopathic progressive polyneuropathy, polyneuropathy in collagen vascular disease, critical illness polyneuropathy, demyelinating polyneuropathy, chronic polyneuropathy, polyradiculoneuropathy, polyneuritis, toxic polyneuropathy, organophosphate-induced delayed polyneuropathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.